What are treatment options for resistance to or intolerance of first-line TKIs in chronic myelogenous leukemia (CML)?

Updated: Oct 23, 2019
  • Author: Rossa Khalaf, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


The risk of progression is high after failure of dasatinib or nilotinib, and no clear evidence suggests that switching to different TKI in such cases will improve long-term outcomes. [19] Options include the following:

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!